NCT00523848 · OUTCOME

Complete Response Rate

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma · Source last updated 2017-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: Every 3 months

Analysis population: Evaluable patients.

Groups in this outcome

VDT: VELCADE, Doxil and Low-dose Thalidomide

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
VDT: VELCADE, Doxil and Low-dose Thalidomide	40

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
VDT: VELCADE, Doxil and Low-dose Thalidomide	22.50	Not reported	10.84	38.45	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
10.84
upper Limit
38.45
value
22.50

denoms

counts
group Id
OG000
value
40
units
Participants

dispersion Type

95% Confidence Interval

groups

id
OG000
title
VDT: VELCADE, Doxil and Low-dose Thalidomide

param Type

NUMBER

population Description

Evaluable patients.

reporting Status

POSTED

time Frame

Every 3 months

title

Complete Response Rate

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice